ASCO 2024: ARV-766, a PROTAC Androgen Receptor Degrader, in mCRPC: Initial Results of a Phase 1/2 Study urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
New research and treatment advances from Yale Canc newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
New Research and Treatment Advances From Yale Canc newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.